State-of-the-Art Treatments for Sarcoidosis
References
- Hunninghake GW, Costabel U, Ando M, et al. ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other G ranulomatous Disorders. Sarcoidosis Vasc Diffuse Lung Dis. 1999 Sep;16(2):149-73.
- Crouser ED, Maier LA, Wilson KC, et al. Diagnosis and Detection of Sarcoidosis. An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med. 2020 Apr 15;201(8):e26-e51. doi: 10.1164/rccm.202002-0251ST
- Birnie D, Ha AC, Gula LJ, Chakrabarti S, Beanlands RS, Nery P. Cardiac Sarcoidosis. Clin Chest Med. 2015 Dec;36(4):657-68. doi: 10.1016/j.ccm.2015.08.008
- Kandolin R, Lehtonen J, Airaksinen J, et al. Cardiac sarcoidosis: epidemiology, characteristics, and outcome over 25 years in a nationwide study. Circulation. 2015 Feb 17;131(7):624-32. doi: 10.1161/CIRCULATIONAHA.114.011522
- Baughman RP, Nagai S, Balter M, et al. Defining the clinical outcome status (COS) in sarcoidosis: results of WASOG Task Force. Sarcoidosis Vasc Diffuse Lung Dis. 2011 Jul;28(1):56-64.
- Thillai M, Atkins CP, Crawshaw A, et al. BTS Clinical Statement on pulmonary sarcoidosis. Thorax. 2021 Jan;76(1):4-20. doi: 10.1136/thoraxjnl-2019-214348
- Judson MA. The treatment of pulmonary sarcoidosis. Respir Med. 2012 Oct;106(10):1351-61. doi: 10.1016/j.rmed.2012.01.013
- Terasaki F, Azuma A, Anzai T, et al; Japanese Circulation Society Joint Working Group. JCS 2016 Guideline on Diagnosis and Treatment of Cardiac Sarcoidosis - Digest Version. Circ J. 2019 Oct 25;83(11):2329-2388. doi: 10.1253/circj.CJ-19-0508
- Vita
T,
Okada
DR,
Veillet-Chowdhury
M, et al.
Complementary Value of Cardiac Magnetic Resonance Imaging and
Positron Emission Tomography/Computed Tomography in the Assessment of
Cardiac Sarcoidosis. Circ Cardiovasc
Imaging. 2018
Jan;11(1):
e007030 . doi: 10.1161/CIRCIMAGING.117.007030 - Kawai H, Sarai M, Kato Y, et al. Diagnosis of isolated cardiac sarcoidosis based on new guidelines. ESC Heart Fail. 2020 Oct;7(5):2662-2671. doi: 10.1002/ehf2.12853
- Kirkil G, Lower EE, Baughman RP. Predictors of Mortality in Pulmonary Sarcoidosis. Chest. 2018 Jan;153(1):105-113. doi: 10.1016/j.chest.2017.07.008
- Kouranos V, Ward S, Kokosi MA, et al. Mixed Ventilatory Defects in Pulmonary Sarcoidosis: Prevalence and Clinical Features. Chest. 2020 Nov;158(5):2007-2014. doi: 10.1016/j.chest.2020.04.074
- Birnie DH, Sauer WH, Bogun F, et al. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm. 2014 Jul;11(7):1305-23. doi: 10.1016/j.hrthm.2014.03.043
- Baughman RP, Valeyre D, Korsten P, et al. ERS clinical practice guidelines on treatment of sarcoidosis. Eur Respir J. 2021 Dec 16;58(6):2004079. doi: 10.1183/13993003.04079-2020
- Coulden
RA,
Sonnex
EP,
Abele
JT,
Crean
AM. Utility of FDG
PET and Cardiac MRI in Diagnosis and Monitoring of Immunosuppressive
Treatment in Cardiac Sarcoidosis. Radiol
Cardiothorac Imaging. 2020
Aug
27;2(4):
e190140 . doi: 10.1148/ryct.2020190140 - Paramothayan NS, Lasserson TJ, Jones PW. Corticosteroids for pulmonary sarcoidosis. Cochrane Database Syst Rev. 2005 Apr 18;2005(2):CD001114. doi: 10.1002/14651858.CD001114.pub2
- James DG, Carstairs LS, Trowell J, Sharma OP. Treatment of sarcoidosis. Report of a controlled therapeutic trial. Lancet. 1967 Sep 9;2(7515):526-8. doi: 10.1016/s0140-6736(67)90493-x
- Zaki MH, Lyons HA, Leilop L, Huang CT. Corticosteroid therapy in sarcoidosis. A five-year, controlled follow-up study. N Y State J Med. 1987 Sep;87(9):496-9.
- Pietinalho A, Tukiainen P, Haahtela T, Persson T, Selroos O; Finnish Pulmonary Sarcoidosis Study Group. Early treatment of stage II sarcoidosis improves 5-year pulmonary function. Chest. 2002 Jan;121(1):24-31. doi: 10.1378/chest.121.1.24
- Gottlieb JE, Israel HL, Steiner RM, Triolo J, Patrick H. Outcome in sarcoidosis. The relationship of relapse to corticosteroid therapy. Chest. 1997 Mar;111(3):623-31. doi: 10.1378/chest.111.3.623
- Broos CE, Poell LHC, Looman CWN, et al. No evidence found for an association between prednisone dose and FVC change in newly-treated pulmonary sarcoidosis. Respir Med. 2018 May;138S:S31-S37. doi: 10.1016/j.rmed.2017.10.022
- Baughman RP, Iannuzzi MC, Lower EE, et al. Use of fluticasone in acute symptomatic pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2002 Oct;19(3):198-204.
- McKinzie BP, Bullington WM, Mazur JE, Judson MA. Efficacy of short-course, low-dose corticosteroid therapy for acute pulmonary sarcoidosis exacerbations. Am J Med Sci. 2010 Jan;339(1):1-4. doi: 10.1097/MAJ.0b013e3181b97635
- Panselinas E, Judson MA. Acute pulmonary exacerbations of sarcoidosis. Chest. 2012 Oct;142(4):827-836. doi: 10.1378/chest.12-1060
- Khan NA, Donatelli CV, Tonelli AR, et al. Toxicity risk from glucocorticoids in sarcoidosis patients. Respir Med. 2017 Nov;132:9-14. doi: 10.1016/j.rmed.2017.09.003
- Baughman RP, Scholand MB, Rahaghi FF. Clinical phenotyping: role in treatment decisions in sarcoidosis. Eur Respir Rev. 2020 Mar 20;29(155):190145. doi: 10.1183/16000617.0145-2019
- Cremers JP, Drent M, Bast A, et al. Multinational evidence-based World Association of Sarcoidosis and Other Granulomatous Disorders recommendations for the use of methotrexate in sarcoidosis: integrating systematic literature research and expert opinion of sarcoidologists worldwide. Curr Opin Pulm Med. 2013 Sep 1;19(5):545-561. doi: 10.1097/MCP.0b013e3283642a7a
- Fang C, Zhang Q, Wang N, Jing X, Xu Z. Effectiveness and tolerability of methotrexate in pulmonary sarcoidosis: A single center real-world study. Sarcoidosis Vasc Diffuse Lung Dis. 2019;36(3):217-227. doi: 10.36141/svdld.v36i3.8449
- Vorselaars ADM, Wuyts WA, Vorselaars VMM, et al. Methotrexate vs azathioprine in second-line therapy of sarcoidosis. Chest. 2013 Sep;144(3):805-812. doi: 10.1378/chest.12-1728
- Müller-Quernheim J, Kienast K, Held M, Pfeifer S, Costabel U. Treatment of chronic sarcoidosis with an azathioprine/prednisolone regimen. Eur Respir J. 1999 Nov;14(5):1117-22. doi: 10.1183/09031936.99.14511179
- Sahoo DH, Bandyopadhyay D, Xu M, et al. Effectiveness and safety of leflunomide for pulmonary and extrapulmonary sarcoidosis. Eur Respir J. 2011 Nov;38(5):1145-50. doi: 10.1183/09031936.00195010
- Baughman RP, Lower EE. Leflunomide for chronic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2004 Mar;21(1):43-8. doi: 10.1007/s11083-004-5178-y
- Bonnel RA, Graham DJ. Peripheral neuropathy in patients treated with leflunomide. Clin Pharmacol Ther. 2004 Jun;75(6):580-5. doi: 10.1016/j.clpt.2004.01.016
- Raj R, Nugent K. Leflunomide-induced interstitial lung disease (a systematic review). Sarcoidosis Vasc Diffuse Lung Dis. 2013 Nov 22;30(3):167-76.
- Melles RB, Marmor MF. The Prevalence of Hydroxychloroquine Retinopathy and Toxic Dosing, and the Role of the Ophthalmologist in Reducing Both. Am J Ophthalmol. 2016 Oct;170:240. doi: 10.1016/j.ajo.2016.06.045
- Baughman RP, Lower EE. Evidence-based therapy for cutaneous sarcoidosis. Clin Dermatol. May-Jun 2007;25(3):334-40. doi: 10.1016/j.clindermatol.2007.03.011
- Adams JS, Diz MM, Sharma OP. Effective reduction in the serum 1,25-dihydroxyvitamin D and calcium concentration in sarcoidosis-associated hypercalcemia with short-course chloroquine therapy. Ann Intern Med. 1989 Sep 1;111(5):437-8. doi: 10.7326/0003-4819-111-5-437
- Baltzan M, Mehta S, Kirkham TH, Cosio MG. Randomized trial of prolonged chloroquine therapy in advanced pulmonary sarcoidosis. Am J Respir Crit Care Med. 1999 Jul;160(1):192-7. doi: 10.1164/ajrccm.160.1.9809024
- Hamzeh N, Voelker A, Forssén A, et al. Efficacy of mycophenolate mofetil in sarcoidosis. Respir Med. 2014 Nov;108(11):1663-9. doi: 10.1016/j.rmed.2014.09.013
- Moravan M, Segal BM. Treatment of CNS sarcoidosis with infliximab and mycophenolate mofetil. Neurology. 2009 Jan 27;72(4):337-40. doi: 10.1212/01.wnl.0000341278.26993.22
- Bitoun S, Bouvry D, Borie R, et al. Treatment of neurosarcoidosis: A comparative study of methotrexate and mycophenolate mofetil. Neurology. 2016 Dec 13;87(24):2517-2521. doi: 10.1212/WNL.0000000000003431
- Baughman RP, Drent M, Kavuru M, et al.; Sarcoidosis Investigators. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med. 2006 Oct 1;174(7):795-802. doi: 10.1164/rccm.200603-402OC
- Rossman MD, Newman LS, Baughman RP, et al. A double-blinded, randomized, placebo-controlled trial of infliximab in subjects with active pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2006 Oct;23(3):201-8.
- Baughman RP, Judson MA, Lower EE, et al.; Sarcoidosis Investigators. Infliximab for chronic cutaneous sarcoidosis: a subset analysis from a double-blind randomized clinical trial. Sarcoidosis Vasc Diffuse Lung Dis. 2016 Jan 15;32(4):289-95.
- Gelfand JM, Bradshaw MJ, Stern BJ, et al. Infliximab for the treatment of CNS sarcoidosis: A multi-institutional series. Neurology. 2017 Nov 14;89(20):2092-2100. doi: 10.1212/WNL.0000000000004644
- Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001 Oct 11;345(15):1098-104. doi: 10.1056/NEJMoa011110
- Gilotra NA, Wand AL, Pillarisetty A, et al. Clinical and Imaging Response to Tumor Necrosis Factor Alpha Inhibitors in Treatment of Cardiac Sarcoidosis: A Multicenter Experience. J Card Fail. 2021 Jan;27(1):83-91. doi: 10.1016/j.cardfail.2020.08.013
- Minnis PA, Poland M, Keane MP, Donnelly SC. Adalimumab for refractory pulmonary sarcoidosis. Ir J Med Sci. 2016 Nov;185(4):969-971. doi: 10.1007/s11845-015-1363-9
- Judson MA, Baughman RP, Costabel U, et al. Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis. Eur Respir J. 2014 Nov;44(5):1296-307. doi: 10.1183/09031936.00000914
- Park MK, Fontana Jr, Babaali H, et al. Steroid-sparing effects of pentoxifylline in pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2009 Jul;26(2):121-31.
- Baughman
RP,
Judson
MA,
Culver
DA, et al.
Roflumilast (Daliresp®) to reduce acute pulmonary events
in fibrotic sarcoidosis: a multi-center, double blind, placebo controlled,
randomized clinical trial. Sarcoidosis Vasc Diffuse
Lung Dis.
2021;38(3):
e2021035 . doi: 10.36141/svdld.v38i3.11684 - Baughman RP, Judson MA, Ingledue R, Craft NL, Lower EE. Efficacy and safety of apremilast in chronic cutaneous sarcoidosis. Arch Dermatol. 2012 Feb;148(2):262-4. doi: 10.1001/archdermatol.2011.301
- Sweiss NJ, Lower EE, Mirsaeidi M, et al. Rituximab in the treatment of refractory pulmonary sarcoidosis. Eur Respir J. 2014 May;43(5):1525-8. doi: 10.1183/09031936.00224513
- Drake WP, Culver DA, Baughman RP, et al. Phase II Investigation of the Efficacy of Antimycobacterial Therapy in Chronic Pulmonary Sarcoidosis. Chest. 2021 May;159(5):1902-1912. doi: 10.1016/j.chest.2020.12.027
- Baughman RP, Sweiss N, Keijsers R, et al. Repository corticotropin for Chronic Pulmonary Sarcoidosis. Lung. 2017 Jun;195(3):313-322. doi: 10.1007/s00408-017-9994-4
- Friedman MA, Le B, Stevens J, et al. Tofacitinib as a Steroid-Sparing Therapy in Pulmonary Sarcoidosis, an Open-Label Prospective Proof-of-Concept Study. Lung. 2021 Apr;199(2):147-153. doi: 10.1007/s00408-021-00436-8
- Ungprasert P, Wetter DA, Crowson CS, Matteson EL. Epidemiology of cutaneous sarcoidosis, 1976-2013: a population-based study from Olmsted County, Minnesota. J Eur Acad Dermatol Venereol. 2016 Oct;30(10):1799-1804. doi: 10.1111/jdv.13760
- Jones E, Callen JP. Hydroxychloroquine is effective therapy for control of cutaneous sarcoidal granulomas. J Am Acad Dermatol. 1990 Sep;23(3 Pt 1):487-9. doi: 10.1016/0190-9622(90)70246-e
- Judson MA, Baughman RP, Costabel U, et al.; Centocor T48 Sarcoidosis Investigators. Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial. Eur Respir J. 2008 Jun;31(6):1189-96. doi: 10.1183/09031936.00051907
- Droitcourt C, Rybojad M, Porcher R, et al. A randomized, investigator-masked, double-blind, placebo-controlled trial on thalidomide in severe cutaneous sarcoidosis. Chest. 2014 Oct;146(4):1046-1054. doi: 10.1378/chest.14-0015
- Baughman RP, Lower EE, Ingledue R, Kaufman AH. Management of ocular sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2012 Mar;29(1):26-33. PMID: 23311120.
- Baughman RP, Papanikolaou I. Current concepts regarding calcium metabolism and bone health in sarcoidosis. Curr Opin Pulm Med. 2017 Sep;23(5):476-481. doi: 10.1097/MCP.0000000000000400
- Kazmirczak
F,
Chen
KA,
Adabag
S, et al. Assessment
of the 2017 AHA/ACC/HRS Guideline Recommendations for Implantable
Cardioverter-Defibrillator Implantation in Cardiac
Sarcoidosis. Circ Arrhythm Electrophysiol.
2019
Sep;12(9):
e007488 . doi: 10.1161/CIRCEP.119.007488 - Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2018 Oct 2;72(14):e91-e220. doi: 10.1016/j.jacc.2017.10.054
- Towbin JA, McKenna WJ, et al. 2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy. Heart Rhythm. 2019 Nov;16(11):e301-e372. doi: 10.1016/j.hrthm.2019.05.007
- Jefic D, Joel B, Good E, et al. Role of radiofrequency catheter ablation of ventricular tachycardia in cardiac sarcoidosis: report from a multicenter registry. Heart Rhythm. 2009 Feb;6(2):189-95. doi: 10.1016/j.hrthm.2008.10.039
- Padala SK, Peaslee S, Sidhu MS, Steckman DA, Judson MA. Impact of early initiation of corticosteroid therapy on cardiac function and rhythm in patients with cardiac sarcoidosis. Int J Cardiol. 2017 Jan 15;227:565-570. doi: 10.1016/j.ijcard.2016.10.101
- Yazaki Y, Isobe M, Hiroe M, et al; Central Japan Heart Study Group. Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone. Am J Cardiol. 2001 Nov 1;88(9):1006-10. doi: 10.1016/s0002-9149(01)01978-6
- Chapelon-Abric C, de Zuttere D, Duhaut P, et al. Cardiac sarcoidosis: a retrospective study of 41 cases. Medicine (Baltimore). 2004 Nov;83(6):315-334. doi: 10.1097/01.md.0000145367
- Zhou Y, Lower EE, Li HP, Costea A, Attari M, Baughman RP. Cardiac Sarcoidosis: The Impact of Age and Implanted Devices on Survival. Chest. 2017 Jan;151(1):139-148. doi: 10.1016/j.chest.2016.08.1457
- Nagai S, Yokomatsu T, Tanizawa K, et al. Treatment with methotrexate and low-dose corticosteroids in sarcoidosis patients with cardiac lesions. Intern Med. 2014;53(23):2761. doi: 10.2169/internalmedicine.53.3120.
- Rosenthal
DG,
Parwani
P,
Murray
TO, et al. Long-Term
Corticosteroid-Sparing Immunosuppression for Cardiac
Sarcoidosis. J Am Heart Assoc.
2019
Sep
17;8(18):
e010952 . doi: 10.1161/JAHA.118.010952 - Griffin JM, Chasler J, Wand AL, et al. Management of Cardiac Sarcoidosis Using Mycophenolate Mofetil as a Steroid-Sparing Agent. J Card Fail. 2021 Dec;27(12):1348-1358. doi: 10.1016/j.cardfail.2021.06.010
- Baker MC, Sheth K, Witteles R, Genovese MC, Shoor S, Simard JF. TNF-alpha inhibition for the treatment of cardiac sarcoidosis. Semin Arthritis Rheum. 2020 Jun;50(3):546-552. doi: 10.1016/j.semarthrit.2019.11.004
- Ballul T, Borie R, Crestani B, et al. Treatment of cardiac sarcoidosis: A comparative study of steroids and steroids plus immunosuppressive drugs. Int J Cardiol. 2019 Feb 1;276:208-211. doi: 10.1016/j.ijcard.2018.11.131
- Gupta R, Judson MA, Baughman RP. Management of Advanced Pulmonary Sarcoidosis. Am J Respir Crit Care Med. 2021 Nov 23. doi: 10.1164/rccm.202106-1366CI. Online ahead of print.
- Shlobin OA, Kouranos V, Barnett SD, et al. Physiological predictors of survival in patients with sarcoidosis-associated pulmonary hypertension: results from an international registry. Eur Respir J. 2020 May 14;55(5):1901747. doi: 10.1183/13993003.01747-2019
- Abston E, Moll M, Hon S, Govender P, Berman J, Farber H. Long-term outcomes of epoprostenol therapy in sarcoid associated pulmonary hypertension. Sarcoidosis Vasc Diffuse Lung Dis. 2020;37(2):184-191. doi: 10.36141/svdld.v37i2.9150
- Abston E, Hon S, Lawrence R, Berman J, Govender P, Farber HW. Treatment of newly diagnosed sarcoid-associated pulmonary hypertension with ambrisentan and tadalafil combination therapy. Sarcoidosis Vasc Diffuse Lung Dis. 2020;37(2):234-238. doi: 10.36141/svdld.v37i2.9343
- Baughman RP, Culver DA, Cordova FC, et al. Bosentan for sarcoidosis-associated pulmonary hypertension: a double-blind placebo controlled randomized trial. Chest. 2014 Apr;145(4):810-817. doi: 10.1378/chest.13-1766
- Baughman RP, Shlobin OA, Gupta R, et al. Riociguat for Sarcoidosis-Associated Pulmonary Hypertension: Results of a 1-Year Double-Blind, Placebo-Controlled Trial. Chest. 2021 Aug 4:S0012-3692(21)03613-8. doi: 10.1016/j.chest.2021.07.2162
- Le Pavec J, Valeyre D, Gazengel P, et al. Lung transplantation for sarcoidosis: outcome and prognostic factors. Eur Respir J. 2021 Aug 5;58(2):2003358. doi: 10.1183/13993003.03358-2020
- Flaherty KR, Wells AU, Cottin V, et al.; INBUILD trial investigators. Nintedanib in progressive interstitial lung diseases: data from the whole INBUILD trial. Eur Respir J. 2021 Sep 2:2004538. doi: 10.1183/13993003.04538-2020. Online ahead of print.
- Fritz D, van de Beek D, Brouwer MC. Clinical features, treatment and outcome in neurosarcoidosis: systematic review and meta-analysis. BMC Neurol. 2016 Nov 15;16(1):220. doi: 10.1186/s12883-016-0741-x
- Joubert B, Chapelon-Abric C, Biard L, et al. Association of Prognostic Factors and Immunosuppressive Treatment With Long-term Outcomes in Neurosarcoidosis. JAMA Neurol. 2017 Nov 1;74(11):1336-1344. doi: 10.1001/jamaneurol.2017.2492
- Lower EE, Broderick JP, Brott TG, Baughman RP. Diagnosis and management of neurological sarcoidosis. Arch Intern Med. 1997 Sep 8;157(16):1864-8. PMID: 9290546.
- Cohen Aubart F, Bouvry D, Galanaud D, et al. Long-term outcomes of refractory neurosarcoidosis treated with infliximab. J Neurol. 2017 May;264(5):891-897. doi: 10.1007/s00415-017-8444-9
- Naz I, Ozalevli S, Ozkan S, Sahin H. Efficacy of a Structured Exercise Program for Improving Functional Capacity and Quality of Life in Patients With Stage 3 and 4 Sarcoidosis: A RANDOMIZED CONTROLLED TRIAL. J Cardiopulm Rehabil Prev. 2018 Mar;38(2):124-130. doi: 10.1097/HCR.0000000000000307
- Wallaert B, Kyheng M, Labreuche J, Stelianides S, Wemeau L, Grosbois JM. Long-term effects of pulmonary rehabilitation on daily life physical activity of patients with stage IV sarcoidosis: A randomized controlled trial. Respir Med Res. 2020 Mar;77:1-7. doi: 10.1016/j.resmer.2019.10.003
- Karadallı MN, Boşnak-Güçlü M, Camcıoğlu B, Kokturk N, Türktaş H. Effects of Inspiratory Muscle Training in Subjects With Sarcoidosis: A Randomized Controlled Clinical Trial. Respir Care. 2016 Apr;61(4):483-94. doi: 10.4187/respcare.04312
- Lower EE, Harman S, Baughman RP. Double-blind, randomized trial of dexmethylphenidate hydrochloride for the treatment of sarcoidosis-associated fatigue. Chest. 2008 May;133(5):1189-95. doi: 10.1378/chest.07-2952
- Lower EE, Malhotra A, Surdulescu V, Baughman RP. Armodafinil for sarcoidosis-associated fatigue: a double-blind, placebo-controlled, crossover trial. J Pain Symptom Manage. 2013 Feb;45(2):159-69. doi: 10.1016/j.jpainsymman.2012.02.016
- Vis R, van de Garde EMW, Meek B, Korenromp IHE, Grutters JC. Randomised, placebo-controlled trial of dexamethasone for quality of life in pulmonary sarcoidosis. Respir Med. 2020 Apr-May;165:105936. doi: 10.1016/j.rmed.2020.105936
- Tavee J, Culver D. Sarcoidosis and small-fiber neuropathy. Curr Pain Headache Rep. 2011 Jun;15(3):201-6. doi: 10.1007/s11916-011-0180-8
- Tavee JO, Karwa K, Ahmed Z, Thompson N, Parambil J, Culver DA. Sarcoidosis-associated small fiber neuropathy in a large cohort: Clinical aspects and response to IVIG and anti-TNF alpha treatment. Respir Med. 2017 May;126:135-138. doi: 10.1016/j.rmed.2017.03.011
DOI: https://doi.org/10.14797/mdcvj.1068 | Journal eISSN: 1947-6108
Language: English
Page range: 94 - 105
Submitted on: Nov 19, 2021
Accepted on: Feb 1, 2022
Published on: Mar 14, 2022
Published by: Houston Methodist DeBakey Heart & Vascular Center
In partnership with: Paradigm Publishing Services
© 2022 Ilias C. Papanikolaou, Emmanouil Antonakis, Aggeliki Pandi, published by Houston Methodist DeBakey Heart & Vascular Center
This work is licensed under the Creative Commons Attribution-NonCommercial 4.0 License.